Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.

Zhang P. et al, (2021), Cancer Res, 81, 1667 - 1680

A decade of LARP society.

Blagden SP. et al, (2021), RNA Biol, 18, 157 - 158

LARP1 isoform expression in human cancer cell lines.

Schwenzer H. et al, (2021), RNA Biol, 18, 237 - 247

A source of hope for platinum-resistant ovarian cancer?

Blagden SP. and Nicum S., (2021), Lancet, 397, 254 - 256

The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction.

Smith EM. et al, (2021), Nucleic Acids Res, 49, 458 - 478

The Oxford Classic links epithelial-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers

AHMED A. et al, (2021), Clinical Cancer Research

Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells.

Dermit M. et al, (2020), Dev Cell, 55, 298 - 313.e10

Invasive group A streptococcal infections in North West England: epidemiology, risk factors and fatal infection.

Blagden S. et al, (2020), Public Health, 186, 63 - 70

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.

Blagden SP. et al, (2020), Lancet Oncol, 21, 969 - 977

Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits

Di Giovannantonio M. et al, (2020), Journal of Medical Genetics

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.

Kapacee ZA. et al, (2020), Med Oncol, 37

Quality of Life with weekly platinum-based chemotherapy in newly diagnosed Ovarian Cancer: the ICON8 phase III randomised controlled clinical trial

BLAGDEN S. et al, (2020), The Lancet Oncology

Controversies around the function of LARP1

Berman AJ. et al, (2020), RNA Biology

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.

Brown NF. et al, (2020), BMC Cancer, 20

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Oza AM. et al, (2020), Clin Cancer Res, 26, 1009 - 1016

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

Blagden SP. et al, (2020), British Journal of Cancer

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.

Clamp AR. et al, (2019), Lancet, 394, 2084 - 2095

New challenges in psycho-oncology: Using drug development methodology to improve survivorship and supportive care intervention trials.

Howells L. et al, (2019), Psychooncology, 28, 1362 - 1366

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak G. et al, (2019), Br J Cancer, 120, 975 - 981

Combining conventional therapy with immunotherapy: A risky business?

Coosemans A. et al, (2019), Eur J Cancer, 113, 41 - 44